Chlamydia psittaci: A Comprehensive Veterinary Reference on Avian Chlamydiosis

Introduction

Chlamydia psittaci is an obligate intracellular, Gram-negative bacterium and the primary etiologic agent of avian chlamydiosis, a systemic disease affecting a broad range of avian species [1]. The organism is also a significant zoonotic pathogen, capable of causing psittacosis (parrot fever) in humans following exposure to infected birds or their contaminated environments [1, 2]. C. psittaci is characterized by a unique biphasic developmental cycle that alternates between infectious, metabolically inactive elementary bodies (EBs) and replicative, non-infectious reticulate bodies (RBs) [1]. This cycle is fundamental to its pathogenesis, transmission, and persistence within host populations. The pathogen exhibits extensive genetic heterogeneity, with multiple genotypes and sequence types (STs) that correlate with host preference and geographic distribution [3, 4]. Understanding the biology, epidemiology, and diagnostic approaches for C. psittaci is critical for veterinary practitioners, diagnosticians, and public health officials.

Taxonomy and Genomic Diversity

C. psittaci belongs to the family Chlamydiaceae, order Chlamydiales [1]. The species is genetically diverse, with whole-genome sequencing of 61 strains revealing four major phylogenetic clades (PG1 to PG4) [4]. Clade 1 represents the most recent lineage and contains the majority of psittacine and human isolates, including the type strain 6BC [4]. Clades 2 through 4 contain strains from diverse non-psittacine avian hosts, as well as mammalian hosts such as ruminants, swine, and horses [4]. This clade structure correlates with host preference and is associated with specific genomic features, including variations in the plasticity zone (PZ), the major outer membrane protein (MOMP) encoded by ompA, and repertoires of inclusion membrane proteins (Incs) and polymorphic membrane proteins (Pmps) [4].

Multilocus sequence typing (MLST) and ompA genotyping are commonly used for molecular epidemiology [3]. The ompA gene encodes the major outer membrane porin, and sequence variation in this gene can result in three-dimensional structural changes in immunogenic domains [4]. Common ompA genotypes include A, B, C, D, E, and F, with genotype A being highly prevalent in psittacine birds and genotype B frequently identified in pigeons and other columbiforms [5, 3, 6]. In a study of live poultry markets in central China, genotype B was the only type detected in poultry and environmental samples [5]. In Australasia, ST24 (typically associated with ompA genotype A) is a dominant clonal lineage found in psittacines, horses, and humans, suggesting recent population expansion and potential cross-host transmission events [3, 34]. The genomic analysis of 61 strains has also shown that past host changes in Clade 3 and 4 strains may be associated with the loss of a MAC/perforin domain in the PZ [4].

Pathogenesis and Host Cell Interactions

The pathogenesis of C. psittaci infection begins with the attachment of EBs to host epithelial cells, primarily in the respiratory and gastrointestinal tracts [1]. The polymorphic membrane protein 17G (Pmp17G) has been identified as a key adhesin that mediates binding and invasion by interacting with and activating the epidermal growth factor receptor (EGFR) on host cells [7]. This interaction triggers EGFR phosphorylation, which recruits the adaptor protein Grb2 and initiates a signaling cascade that facilitates chlamydial internalization [7]. Following entry, the EB-containing endosome avoids lysosomal fusion and differentiates into the metabolically active RB, which replicates within a specialized intracellular compartment called an inclusion [1]. The inclusion membrane is decorated with Inc proteins that modulate host cell functions, including vesicle trafficking, apoptosis, and immune signaling [4]. After multiple rounds of replication, RBs differentiate back into EBs, which are released upon host cell lysis to infect neighboring cells [1].

The host inflammatory response is a major factor in disease progression [33]. Transcriptomic analyses of psittacosis patients have demonstrated markedly elevated expression of pro-inflammatory genes, including interleukins and chemokines [33]. Elevated serum levels of cytokines such as G-CSF, IL-2, IL-6, IL-10, IL-18, IP-10, MCP-3, and TNF-alpha are associated with pneumonia, along with increases in activated neutrophils and decreases in lymphocyte counts [33]. This inflammatory milieu contributes to the immunopathology observed in severe cases.

Host Range and Epidemiology

C. psittaci has an exceptionally broad host range, infecting over 460 avian species across multiple orders, including Psittaciformes (parrots, cockatoos), Columbiformes (pigeons, doves), Galliformes (chickens, turkeys), Anseriformes (ducks, geese), and many others [1, 3]. The pathogen has also been identified in novel avian hosts such as the Australian bustard (Ardeotis australis) and the sooty shearwater (Ardenna grisea) [3]. In addition to birds, C. psittaci can infect a variety of mammals, including horses, cattle, sheep, goats, swine, and rodents [4, 8]. In horses, C. psittaci has emerged as a significant cause of equine reproductive loss in southeastern Australia, with 31 cases identified between 2018 and 2022, predominantly in Victoria and New South Wales during winter and spring [8].

Transmission among birds occurs primarily via the horizontal route through inhalation or ingestion of infectious EBs shed in feces, respiratory secretions, and feather dust [1]. Vertical transmission has also been documented [1]. Asymptomatic infections are common, particularly in psittacine birds, and contribute to the silent spread of the pathogen within flocks and aviaries [6]. A study in Korea found that 36.5% of healthy psittacine birds sampled from zoos, farms, and cafes were positive for C. psittaci, with genotype A being the predominant type [6]. The prevalence of C. psittaci in live poultry markets poses a zoonotic threat, with positivity rates of 4.55% in poultry and environmental samples reported in central China [5]. Pigeon shops had the highest positivity rate (46.67%), and the pathogen was detected in sewage, fecal samples, cage swabs, and air samples [5].

Clinical Manifestations in Birds

Avian chlamydiosis can present as an acute, subacute, or chronic infection, with clinical signs varying by host species, age, immune status, and the virulence of the infecting strain [1]. In psittacine birds, acute disease is characterized by lethargy, anorexia, ruffled feathers, conjunctivitis, rhinitis, dyspnea, and biliverdinuria (green-colored urine) [1]. Chronic infections may present with weight loss, intermittent diarrhea, and sinusitis. In poultry, infections are often subclinical but can cause respiratory signs, decreased egg production, and conjunctivitis [1]. Mortality rates can be high in naive populations, especially in young birds.

Diagnostic Approaches

Accurate and timely diagnosis of C. psittaci infection is essential for effective treatment and control. Traditional diagnostic methods include bacterial culture, serology, and antigen detection, but these have limitations in sensitivity and specificity [1, 9]. Culture requires specialized biosafety level 2 or 3 facilities and is time-consuming [1]. Serological tests, such as complement fixation and ELISA, can detect antibodies but may not distinguish between active and past infection [1].

Molecular diagnostic methods have become the gold standard for detection. Real-time polymerase chain reaction (qPCR) targeting conserved genes such as ompA or the 16S rRNA gene is widely used for rapid and sensitive detection [5, 10]. Loop-mediated isothermal amplification (LAMP) combined with CRISPR/Cas12b has been engineered for C. psittaci detection, achieving a detection limit of 10^2 aM in a two-step reaction and 10^3 aM in a one-tube reaction, with results available within one hour [10]. This assay targets the highly conserved CPSIT_0429 gene and shows no cross-reactivity with other pathogens [10].

Metagenomic next-generation sequencing (mNGS) and targeted next-generation sequencing (tNGS) have revolutionized the diagnosis of C. psittaci pneumonia, particularly in severe or atypical cases [11, 12, 9, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 31, 32, 35]. mNGS provides unbiased, culture-independent detection of all pathogens in a clinical sample, enabling the identification of C. psittaci even when conventional tests are negative [11, 23]. In a multicenter study of 61 pneumonia cases, mNGS played a critical role in diagnosis, with all cases confirmed by this method [11]. mNGS also allows for the simultaneous detection of coinfections, which are common in severe cases [12, 17, 35]. A study of 46 C. psittaci pneumonia patients found that 41.3% had suspected coinfections, with a coinfection rate of 84.2% in the severe group [12]. tNGS, which targets a specific panel of pathogens, offers a more cost-effective alternative to mNGS while maintaining high sensitivity and rapid turnaround times [9, 18].

The following decision tree illustrates the diagnostic workflow for suspected C. psittaci infection in avian patients.

graph TD
    A[Clinical Suspicion of Avian Chlamydiosis], > B{History of avian exposure?};
    B, Yes, > C[Collect samples: conjunctival, choanal, cloacal swabs, feces];
    B, No, > D[Consider other respiratory pathogens];
    C, > E{Initial screening};
    E, qPCR for Chlamydia spp., > F{Result};
    F, Positive, > G[Confirm with species-specific qPCR or sequencing];
    F, Negative, > H[Consider mNGS/tNGS if high clinical suspicion];
    G, C. psittaci confirmed, > I[Initiate treatment and biosecurity measures];
    H, Positive, > I;
    H, Negative, > J[Re-evaluate differential diagnoses];
    I, > K[Monitor treatment response and re-test post-treatment];

Treatment and Antimicrobial Therapy

The treatment of avian chlamydiosis is based on the use of tetracycline-class antibiotics, with doxycycline being the preferred agent [1, 11, 14, 15, 16, 24, 25, 26]. Doxycycline is effective against both EBs and RBs and is administered orally or via injection, typically for a minimum of 45 days to ensure complete clearance of the infection [1]. In severe cases, doxycycline may be combined with quinolones such as moxifloxacin [14, 24, 32]. Omadacycline, a novel aminomethylcycline antibiotic derived from tetracycline, has shown promise in treating severe C. psittaci pneumonia complicated by acute respiratory distress syndrome (ARDS) and multidrug-resistant bacterial infections [27, 13]. In a study of 16 patients with severe psittacosis pneumonia and ARDS, treatment with omadacycline resulted in complete recovery in 14 patients, with two deaths due to secondary infections [13]. Quinolones, including moxifloxacin and levofloxacin, are also effective and may be associated with shorter hospital stays and fever duration [22]. However, tetracyclines remain the first-line therapy [25]. Supportive care, including fluid therapy, nutritional support, and respiratory support, is critical in severe cases [11, 14, 24].

Prevention and Control

Prevention of C. psittaci infection in avian populations relies on strict biosecurity measures, including quarantine of new birds, regular screening, and isolation of infected individuals [1]. In commercial poultry and live bird markets, monitoring programs are essential to detect and control the pathogen [5]. Environmental decontamination is challenging due to the resilience of EBs, which can remain infectious in organic material for several months [1]. Effective disinfectants include quaternary ammonium compounds, bleach (1:10 dilution), and 70% ethanol [1]. Vaccination is not widely available for C. psittaci in birds, and control efforts focus on antimicrobial treatment and management practices.

Frequently Asked Questions

What is the primary mode of transmission for Chlamydia psittaci in birds?

The primary mode of transmission is horizontal, through the inhalation or ingestion of infectious elementary bodies shed in feces, respiratory secretions, and feather dust from infected birds [1].

Which avian species are most commonly affected by Chlamydia psittaci?

Psittacine birds (parrots, cockatoos, macaws) are most commonly affected, but the pathogen infects over 460 avian species, including pigeons, poultry, and waterfowl [1, 3].

What is the gold standard diagnostic test for Chlamydia psittaci in birds?

Real-time polymerase chain reaction (qPCR) targeting conserved genes such as ompA is the gold standard for rapid and sensitive detection [5, 10]. Metagenomic next-generation sequencing (mNGS) is increasingly used for comprehensive pathogen detection, especially in severe or atypical cases [11, 23].

What is the recommended treatment for avian chlamydiosis?

Doxycycline is the preferred antimicrobial agent, typically administered for a minimum of 45 days [1, 11]. Quinolones such as moxifloxacin may be used in combination for severe cases [14, 24].

Can Chlamydia psittaci infect mammals other than birds?

Yes, C. psittaci can infect a variety of mammals, including horses, cattle, sheep, goats, swine, and rodents [4, 8]. In horses, it is a recognized cause of reproductive loss [8].

What are the key genomic features associated with host preference in Chlamydia psittaci?

Phylogenetic clade membership, ompA genotype, and plasticity zone (PZ) structure are associated with host preference [4]. Clade 1 contains most psittacine and human isolates, while clades 2-4 contain strains from diverse non-psittacine hosts [4].

How long does it take to obtain results from mNGS for Chlamydia psittaci detection?

mNGS results are typically available within 24 to 72 hours from sample receipt [13, 23].

What is the role of the Pmp17G protein in Chlamydia psittaci infection?

Pmp17G is a polymorphic membrane protein that mediates bacterial adhesion to host cells and activates the EGFR signaling pathway to facilitate invasion [7].

Are there any effective vaccines for Chlamydia psittaci in birds?

No widely available commercial vaccines exist for C. psittaci in birds; control relies on antimicrobial treatment and biosecurity [1].

What is the significance of asymptomatic carriers in the epidemiology of Chlamydia psittaci?

Asymptomatic carriers, which are common in psittacine birds, shed the pathogen intermittently and contribute to silent transmission within flocks and to humans [2, 6].

References

[1] Jiewen Wang, Buwei Wang, Jian Xiao et al. Chlamydia psittaci: A zoonotic pathogen causing avian chlamydiosis and psittacosis. Virulence, 2024. URL: https://www.semanticscholar.org/paper/9c0792b90a401644c2b95f238c871d740d15945a

[2] Zhenjie Zhang, Hong Zhou, H. Cao et al. Human-to-human transmission of Chlamydia psittaci in China, 2020: an epidemiological and aetiological investigation. The Lancet Microbe, 2022. URL: https://www.semanticscholar.org/paper/22c797c4c5fc9f398726ff264f82daaaa9cfdf2f

[3] V. Kasimov, Rhys Thomas White, J. Foxwell et al. Whole-genome sequencing of Chlamydia psittaci from Australasian avian hosts: A genomics approach to a pathogen that still ruffles feathers. Microbial Genomics, 2023. URL: https://www.semanticscholar.org/paper/c0d12e0823a839e1a64ad47ebfe6e4903a7c1992

[4] K. Sachse, M. Hölzer, F. Vorimore et al. Genomic analysis of 61 Chlamydia psittaci strains reveals extensive divergence associated with host preference. BMC Genomics, 2023. URL: https://www.semanticscholar.org/paper/600ef13cbf1d268c1f06e3351e3a691ac5494f86

[5] Ru-sheng Zhang, Huiyuan Fu, Can Luo et al. Chlamydia psittaci detected at a live poultry wholesale market in central China. BMC Infectious Diseases, 2024. URL: https://www.semanticscholar.org/paper/28b7219280ec871ee22a18f3983c4a6abc0cb942

[6] Hye-Jin Lee, O. Lee, Sung-Il Kang et al. Prevalence of asymptomatic infections of Chlamydia psittaci in psittacine birds in Korea. Zoonoses and Public Health, 2023. URL: https://www.semanticscholar.org/paper/0d40b8a8c08a937620e0d176712e247000762a9a

[7] Xiaohui Li, Zonghui Zuo, Yihui Wang

[8] C. El-Hage, A. Legione, J. Devlin et al. Equine Psittacosis and the Emergence of Chlamydia psittaci as an Equine Abortigenic Pathogen in Southeastern Australia: A Retrospective Data Analysis. Animals, 2023. URL: https://www.semanticscholar.org/paper/cf30297f67dabcc2554cfbb1c0b54db302866d29

[9] Xinsheng Yan, H. Fu, Wenjun Deng et al. Early and rapid diagnosis of Chlamydia psittaci pneumonia by tNGS in six patients: a case series. Frontiers in Medicine, 2024. URL: https://www.semanticscholar.org/paper/decc2440dd3716a2e762e192e7df94acbef369d9

[10] Rong Wang, X. Mao, Jian Xu et al. Engineering of the LAMP-CRISPR/Cas12b platform for Chlamydia psittaci detection. Journal of Medical Microbiology, 2023. URL: https://www.semanticscholar.org/paper/d5ce4ceedc7038d75261c4df086673150b2bd3e4

[11] Hui Deng, Yeshuang Shi, Mei Xie et al. Diagnosis and treatment experience of Chlamydia psittaci pneumonia: A multicenter retrospective study in China. BMC Infectious Diseases, 2024. URL: https://www.semanticscholar.org/paper/ddd186b85276a33acd16933152dab2378b532e0a

[12] Lei Yuan, Qiang Chen, X. Zhu et al. Evaluation of clinical characteristics and risk factors associated with Chlamydia psittaci infection based on metagenomic next-generation sequencing. BMC Microbiology, 2024. URL: https://www.semanticscholar.org/paper/8a61d056d506775b07080629ead3003fe76aa230

[13] Dao-Xin Wang, Ling-Xi Xiao, Xin-yu Deng et al. Omadacycline for the treatment of severe pneumonia caused by Chlamydia psittaci complicated with acute respiratory distress syndrome during the COVID-19 pandemic. Frontiers in Medicine, 2024. URL: https://www.semanticscholar.org/paper/5972ab7df05bc8df50946909593a4e50a363160af

[14] Lujuan He, Hongzhong Yang, Shenggang Liu et al. Physiological analysis of severe chlamydia psittaci pneumonia and clinical diagnosis after doxycycline-based treatment. Frontiers in Physiology, 2023. URL: https://www.semanticscholar.org/paper/6a3f896ed29101cff4480c0a9126966c1dbbe335

[15] Yubo Huang, Wenzheng Zheng, W. Gan et al. Chlamydia psittaci pneumonia: a clinical analysis of 12 patients. Annals of Translational Medicine, 2023. URL: https://www.semanticscholar.org/paper/a7efb538dcc25fa328a46aee26fe4046bd4e04d5

[16] Jinmeng Dai, Xue Lian, J. Mo et al. Case report: A clinical case study of six patients with Chlamydia psittaci pneumonia. Frontiers in Cellular and Infection Microbiology, 2023. URL: https://www.semanticscholar.org/paper/c640a76ce720b1ff2f54067c8817d987445e948f

[17] Gongxun Xie, Qing Hu, Xuefang Cao et al. Clinical identification and microbiota analysis of Chlamydia psittaci- and Chlamydia abortus- pneumonia by metagenomic next-generation sequencing. Frontiers in Cellular and Infection Microbiology, 2023. URL: https://www.semanticscholar.org/paper/933cc311745b7b635a66764396aabc4c9cd71bcd

[18] Yanping Zhang, Xiangsen Jiang, W. Ye et al. Clinical features and outcome of eight patients with Chlamydia psittaci pneumonia diagnosed by targeted next generation sequencing. Clinical Respiratory Journal, 2023. URL: https://www.semanticscholar.org/paper/df7314b841c91e0c7072f6b2775149b84a775527

[19] Fuxun Yang, Jiajia Li, Boyang Qi et al. Clinical Symptoms and Outcomes of Severe Pneumonia Caused by Chlamydia psittaci in Southwest China. Frontiers in Cellular and Infection Microbiology, 2022. URL: https://www.semanticscholar.org/paper/e3f1484c1d168aa17354f92189b9aee6447431ad

[20] Yunfeng Shi, Junxian Chen, Xiaohan Shi et al. A case of chlamydia psittaci caused severe pneumonia and meningitis diagnosed by metagenome next-generation sequencing and clinical analysis: a case report and literature review. BMC Infectious Diseases, 2021. URL: https://www.semanticscholar.org/paper/b89a47e84d3e223bc5e67dd253c675c56105d57d

[21] Xiaoming Yang, Zhongda Liu, Xiaojing Liu et al. Chlamydia Psittaci Pneumonia-Induced Myocarditis: A Case Report. Infection and Drug Resistance, 2023. URL: https://www.semanticscholar.org/paper/9eeb45fb10fe7e53cb430f6906a94c01c47fa170

[22] Min Yang, Dan-hui Yang, Huan-Dong Yang et al. Clinical Characteristics of Chlamydia psittaci Pneumonia Infection in Central South China. Infectious Disease and Therapy, 2022. URL: https://www.semanticscholar.org/paper/54251b399908dc1055724ea77fc7d388ba79c6f6

[23] Xiancheng Chen, K. Cao, Yu Wei et al. Metagenomic next-generation sequencing in the diagnosis of severe pneumonias caused by Chlamydia psittaci. Infection, 2020. URL: https://www.semanticscholar.org/paper/73016a30e749f83ebfd28728ac494ad83eb5efef

[24] Anbing Zhang, Xiuqiong Xia, Xiaoling Yuan et al. Clinical characteristics of 14 cases of severe Chlamydia psittaci pneumonia diagnosed by metagenomic next-generation sequencing. Medicine, 2022. URL: https://www.semanticscholar.org/paper/01a5d766e923a51b53f83be8584c9df8dfd82ce4

[25] Hu Li, B. Hao, Yongxue Wang et al. Metagenomic next‐generation sequencing for the diagnosis of Chlamydia psittaci pneumonia. Clinical Respiratory Journal, 2022. URL: https://www.semanticscholar.org/paper/3e1c56606fc1b4aaf255670d884d5cc2a58ce3b9

[26] Qiaoqiao Yin, Yue-Hong Li, Hongying Pan et al. Atypical pneumonia caused by Chlamydia psittaci during the COVID-19 pandemic. International Journal of Infectious Diseases, 2022. URL: https://www.semanticscholar.org/paper/5c109db6d937b672ab2c5fd82e540a835a48169c

[27] Yong Yang, Cheng Li, Xianshuang Fan et al. Effectiveness of Omadacycline in a Patient with Chlamydia psittaci and KPC-Producing Gram-Negative Bacteria Infection. Infection and Drug Resistance, 2025. URL: https://www.semanticscholar.org/paper/8480ec00c869d6b93f2a9494c7a7b562fae6f95c

[28] N. Yang, Zhengqiu Ou, Qiankun Sun et al. Chlamydia psittaci pneumonia - evolutionary aspects on chest CT. BMC Infectious Diseases, 2025. URL: https://www.semanticscholar.org/paper/2f3877dcb9b097cf27c0070c1de9059f80fc4eb3

[29] Imane Bendjelloul, J. Lourtet-Hascoët, J. Galinier et al. Chlamydia psittaci endocarditis: a case report and literature review. Infectious Diseases Now, 2023. URL: https://www.semanticscholar.org/paper/e8e86756302b439ee1c65e301c55190e833c0a2a

[30] S. Su, Xiaoqing Su, Ling Zhou et al. Severe Chlamydia psittaci pneumonia: clinical characteristics and risk factors. Annals of Palliative Medicine, 2021. URL: https://www.semanticscholar.org/paper/1df218cc0c950055817de714b7eb1d9661633076